Cancer continues to be one of the fastest-growing and most unpredictable drivers of healthcare spend today. But what if the biggest opportunity to better manage that spend is not just about reducing costs, but about ensuring care is delivered correctly from the start? Despite rapid advances in treatment and expanding clinical guidelines, cancer care remains highly variable, even within leading networks. These inconsistencies, from missed diagnostics to suboptimal treatment decisions, can lead to avoidable complications, ineffective therapies, and unnecessary downstream costs.
Join us as we reframe how benefits leaders think about cancer spend by focusing on the role of evidence-based care in shaping total cost of care. We will explore where variation occurs, why it persists, and what happens when care is aligned to the latest standards and subspecialty expertise is introduced at the right moments. We will cover:
- Why cancer care varies more than most employers realize and how that impacts cost
- How gaps in diagnostics, testing, and treatment decisions drive downstream spend
- Why access to subspecialty expertise changes clinical and financial outcomes
- How improving decision-making leads to more consistent, high-value care
- What a population-wide approach to cancer management looks like in practice—and its impact on cancer care ROI
Whether you're shaping benefits, guiding clinical strategy, or advising employers, this session will provide a clearer framework for managing one of the most complex areas of healthcare by shifting the focus from cost containment to getting care right.
